Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BML-260
Cat. No.:
OB0425LY-103
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
BML-260 is a potent and dual-specific phosphatases JSP-1 and DUSP22 inhibitor.
Synonyms:
101439-76-3; 4-(5-Benzylidene-4-oxo-2-thioxothiazolidin-3-yl)benzoic acid; Benzoic acid, 4-[4-oxo-5-(phenylmethylene)-2-thioxo-3-thiazolidinyl]-; 4-{4-oxo-5-[1-Phenyl-meth-(Z)-ylidene]-2-thioxo-thiazolidin-3-yl}-benzoic acid
CAS No.:
101439-76-3
Compound CID:
1565747
Formula:
C17H11NO3S2
Formula Weight:
341.4
Specification
Target:
STAT; PPAR
Pathway:
JAK/STAT signaling; Stem cell/Wnt; Cell cycle/DNA damage; Metabolic enzyme/Protease; Vitamin D related/Nuclear receptor
Storage:
Storage at -20°C.
Applications:
BML-260 can be used to study inflammatory and proliferative diseases associated with JNK signaling dysfunction and obesity.
